(c) 2014 American Society for Bone and Mineral Research.”
“The aim of the present study was to investigate the adverse outcomes of non-tunneled hemodialysis catheters and determinants in chronic hemodialysis patients receiving care at the Yaounde General Hospital hemodialysis center, Cameroon. This was a prospective study of 11 months duration (February-December 2008) involving 81 non-tunneled non-cuffed
catheters (63 femoral, 18 internal jugular) placed in 72 adults (47 men, 65.3%) on chronic hemodialysis. Baseline clinical and laboratory parameters associated with catheter-related complications during follow-up were investigated. The difference between GW2580 supplier variables was assessed using the (2) test and equivalents. Sixty-five (80.2%) catheters were inserted for emergency dialysis, 11 (13.6%) for
a failed native arteriovenous fistula and five (6.2%) for a failed prior catheter. The mean time-to-catheter removal was 35 +/- 28 days. Catheter-related complications accounted for a third of catheter removals. The main catheter-related complications were infections (17/27, 62.9%) and bleeding (6/27, 22.2%), which were associated with unemployment (P=0.0002) and longer duration YAP-TEAD Inhibitor 1 of catheter (P=0.004). The catheter-related infections were sepsis (11.8%), exit-site (29.4%) and both (58.8%); leading to death in 11/17 (64.7%) cases. Fever (94.1%), pain (88.2%) and pus (70.6%) were the main infectious signs with Staphylococcus aureus involved in 70.6%. Unemployment was significantly frequent in patients with infectious complications (76.5% vs. 26.6%, P=0.0004). Non-tunneled hemodialysis catheters are mainly used for emergency dialysis through the femoral vein in this setting. Catheter-related infections due to Staphylococci are the leading complications associated with unemployment and longer utilization. Efforts are needed to improve early transfer of patients to nephrologists for better preparation for renal replacement therapy.”
“The insulin receptor substrate (IRS) proteins are
key mediators of insulin and insulinlike growth factor 1 (IGF-1) signaling. Protein S3I-201 tyrosine phosphatase (PTP)-1B dephosphorylates and inactivates both insulin and IGF-1 receptors. IRS2-deficient mice present altered hepatic insulin signaling and beta-cell failure and develop type 2-like diabetes. In addition, IRS2 deficiency leads to developmental defects in the nervous system. IGF1 gene mutations cause syndromic sensorineural hearing loss in humans and mice. However, the involvement of IRS2 and PTP1B, two IGF-1 downstream signaling mediators, in hearing onset and loss has not been studied. Our objective was to study the hearing function and cochlear morphology of Irs2-null mice and the impact of PTP1B deficiency.